Detail akcie ProPhase Labs online

Business Summary: ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, ProPhase Labs Inc revenues decreased 64% to $44.4M. Net loss totaled $16.8M vs. income of $18.5M. Revenues reflect Diagnostic services segment decrease of 77% to $24.8M. Net loss reflects Research and development increase from $652K to $1.4M (expense), General and administration increase of less than 1% to $34.5M (expense).